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Abstract
Objective

To evaluate the preferences of patients with osteoarthritis for treatment.

Methods

A discrete-choice experiment was conducted among adult OA patients who were presented with 12
choice sets of two treatment options and asked in each to select the treatment they would prefer.
Based on literature reviews, expert consultation, patient survey and expert meeting, treatment options
were characterized by seven attributes: improvement in pain, improvement in walking, ability to
manage domestic activities, ability to manage social activities, improvement in overall energy and wellbeing, risk of moderate/severe side effects and impact on disease progression. Random parameters
logit model was used to estimate patients’ preferences and a latent class model was conducted to
explore preferences classes.

Results

253 OA patients from seven European countries were included (74% women; mean age 71.3 years).
For all seven treatment attributes, significant differences were observed between levels. Given the
range of levels of each attribute, the most important treatment attribute in this group was impact on
disease progression (29.5%) followed by walking improvement (17.1%) and pain improvement (16.3%).
The latent class model identified two preference classes. In the first class (probability of 56%), patients
valued impact of disease progression the most (39%). In the second class, walking improvement and
improvement in overall energy and well-being were the most important (23%).

Conclusion

This study suggests that all seven treatment attributes were important for OA patients. Overall, given
the range of levels, the most important outcomes were impact on disease progression and
improvement in pain and walking.

Keywords

Discrete-choice experiment, Osteoarthritis, Outcomes, Patient preferences

Introduction

The patient perspective is becoming increasingly important in clinical and regulatory decision-making
[1,2]. Information about what patients prefer, and how they value various aspects of a health
intervention can be useful when designing, evaluating and implementing healthcare programs [3]. Such
insights can also help when establishing treatment guidelines and should be taken into consideration
when designing new drugs or other interventions [4]. There has therefore been a growing interest in
obtaining patients’ preferences for healthcare interventions. In particular, the use of stated-preference
methods (including discrete-choice experiments (DCE)) has markedly increased in recent years [5,6]. A
DCE is a quantitative method used to elicit and quantify the preferences of participants [7] that are
asked to repeatedly choose between hypothetical options that systematically differ in several
attributes of interest.

Given the significant challenges and lack of therapeutic options for osteoarthritis [8], some statedpreference studies have been conducted to elicit preferences for OA treatment [4]. OA is the most
common form of arthritis in later life and most frequently affects the knee, hand, and/or hip [9]. OA is
predominantly characterized by pain and has been shown to substantially reduce the patient's mobility
and quality of life and to represent a significant contributor to disability in the elderly [10]. Currently
OA treatments aims primarily to reduce joint pain, maintain and improve joint mobility and enhance
quality of life. Treatment options (including surgery, pharmacological and non-pharmacological
treatment) may however differ in benefits and risks, emphasizing the need to assess patients’
preferences for different aspects of OA treatment [4].
Previous DCEs conducted in OA were mainly conducted to assess preferences for the characteristics of
OA drug treatment suggesting that DCE is a reliable method in this patient population, but revealed
some contrasting results. Some studies reported that benefit attributes (e.g. pain improvement,
physical improvement) were the most important for patients [11], [12], [13], while others suggested
that patients were mainly concerned by side-effects [14], [15], [16]. However, few studies have
investigated the trade-offs between all potential OA treatment outcomes including impact on pain,
physical mobility, joint structure and side-effects. Further insight into patients’ preferences for OA
patients as well as investigating potential differences in preferences between patients and countries
would thus be worthwhile. The European Society European Society on Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) has therefore set up a working
group to conduct a DCE to further elicit patients’ preferences in OA across European countries.
The aim of this study was therefore to assess the preferences of European patients for OA treatment
outcomes using a DCE. Furthermore, as secondary objectives, we aimed to assess heterogeneity in
responses by determining different preference profiles of participants and revealing potential
differences in preferences between the participating European countries.

Methods

A DCE was used to examine patients´ preferences for OA treatment. In the DCE survey, patients were
presented with a series of choices and asked in each to select the treatment (Treatment A and
Treatment B) they would prefer. The two hypothetical treatments were described by a set of attributes
which were further specified by attributes` levels (see below). Good research practices for statedpreference studies were followed [3,17].

Attributes and levels

The identification and prioritization of important OA treatment attributes was conducted following a 4stage process: (1) two scoping reviews (i.e. an exhaustive review of preference studies in OA, and a
review of outcomes in RCTs of OA treatment) to generate an initial list of OA treatment outcomes; (2)
interviews with OA patients (n=20) to identify any missing outcomes and an expert consultation (n=17)
to review and validate initial outcomes; (3) a patient survey (n=56) with OA patients from Belgium,
Italy, Portugal, Netherlands, Switzerland and the United Kingdom to rank the most important
outcomes; (4) an expert meeting including one OA patient (n=17) to identify the most important OA
treatment outcomes for inclusion in the DCE based on the survey results, and to select levels for each
chosen outcome. More details about the findings of each stage are presented in Appendix A. Finally,

the following seven attributes were included: improvement in pain, improvement in walking, ability to
manage domestic activities, ability to manage social activities, improvement in overall energy and wellbeing, risk of moderate/severe side effects and impact on disease progression (see Table 1). For each
attribute, three or four levels were agreed upon by the expert group.
Table 1. Attributes and levels included in the DCE.
Attributes
Levels
Pain improvement
None
Mild
Moderate
Large
Walking improvement
None
Mild
Moderate
Large
Domestic activities
All domestic activities without difficulty
Some domestic activities with difficulty
All domestic activities with difficulty
Social activities
All social activities without difficulty
Some social activities with difficulty
All social activities with difficulty
Overall energy and well-being improvement None
Mild
Moderate
Large
Risk of severe side effects
1 patient out of 200 within one year (0.5%)
1 patient out of 100 within one year (1%)
1 patient out of 50 within one year (2%)
Impact on disease progression
Improvement in joint structure
No degradation
Mild degradation
Severe degradation

Experimental design

A main-effect efficient design by maximizing the D-efficiency was used to select the subset of choice
sets to be presented to the patients using Ngene software (Version 1.1.1, http://www.choicemetrics.com). A total of 24 choice tasks was designed and blocked into two versions of the
questionnaire containing 12 choice tasks each. A dominance test - a choice set with one hypothetical
treatment that is clearly better than the other (i.e. a treatment associated with higher improvement in
pain, walking and overall energy, better ability to conduct domestic and social activities, similar sideeffects risk and lower impact on disease progression), - was added to assess reliability of respondents’
choices [18]. Each respondent therefore received 13 choice tasks. An example of a choice task is shown
in Fig. 1. All choice tasks for one version of the questionnaire are available on Appendix B (the
dominance test is the choice task number 10).

Fig. 1. Example choice set of the DCE questionnaire.

We did not include an opt-out in the DCE because interviews with OA patients and experts suggested
that participants would be willing to trade-off between hypothetical treatment options, further being
not directly connected to drug options. To avoid larger numbers of respondents who choose the optout option to prevent additional loss of power, we therefore decided to use binary choices and thus
forced a choice.

Questionnaire design

The questionnaire was paper-based. The attributes and levels were first described, and an example of
a completed choice task was included. After respondents had completed the 13 choice tasks, they
were asked how difficult they found the tasks on a seven-point Likert scale. Data on participants’
demographics and socioeconomic (i.e. age, education, gender, and education) and some medical
characteristics (i.e. knee and/or hip OA, treatment for OA, hip/knee replacement) were also collected.
The questionnaire was developed in English by MH and ED, and reviewed and approved by the ESCEO
working group (n=17). The working group consisted of clinical scientists in the field of OA and DCE
experts who were selected by the Scientific Advisory Board of ESCEO. The English version of the
questionnaire was then pilot tested with some clinicians and 20 OA patients to check interpretation
problems, face validity and the length of the questionnaire. Only minor changes to layout were made.
The questionnaire was then translated into additional languages (French, Spanish, German and Italian),
covering the languages spoken across the countries in our sample. Each language version was checked
and approved by at least one additional native speaker. One version of the questionnaire is available in
Appendix B.

Study population, data collection and sample size

The study was conducted in seven European countries including Belgium, France, Italy, the
Netherlands, Portugal, Spain and United Kingdom between May 2018 and July 2019. The DCE was
conducted in OA patients that were recruited during specialist outpatient clinics or from cohort
studies. Participants who were not cognitively able to understand and fill out the questionnaire or
lacked understanding of local language were excluded. The questionnaire was completed by the
participant at the clinic or at home. In the latter case, it was returned in a postage-paid envelope.
Sample size calculation for stated-preference studies is difficult as it depends on the true values of the

unknown parameters estimated in the DCE. Hence, a minimum of 200 respondents was targeted for
the whole sample, which was sufficient based on common rules-of-thumb for minimum sample
size [19] and similar to other DCEs [6].

Ethics approval

Approval for this study was obtained from the Medical Ethics Committee of the University of Liège that
coordinated the project. Participants gave informed written consent. Additional local ethics approval
was obtained at those participating centers that required ethics approval for a DCE questionnaire
study.

Statistical analyses

Data analysis was carried out using Nlogit software, version 5.0. Data of participants who failed the
dominance test were excluded. The available patient data were analysed with various recommended
statistical methods [17].
First, a random parameters logit model was used which allows to capture heterogeneity by estimating
the standard deviation of the parameter's distribution. The model provides mean coefficients as well
as a measure of the distribution around the mean coefficient in the form of a standard deviation. If the
standard deviation is significantly different from zero, this is interpreted as evidence of significant
preference heterogeneity for the attribute/level in the sample. We used a panel model to account for
the panel nature of the data, as each participant completed 12 choice sets. To take scale heterogeneity
into account, which relates to potential differences between countries in the randomness of choice
behaviour, a normally distributed random component was added for each country.
All variables were included as effects-coded categorical variables that we assumed to be normally
distributed. The model was estimated by using 1,000 Halton draws and no interaction terms were
included. Using effect coding, mean attributes are normalized to zero and preference weights are
relative to the mean effect of the different levels of the attribute. The sign of a coefficient reflects
whether an attribute level leads to an increase (positive) or a decrease (negative) on the patients’
utility. The value of each coefficient represents the importance patients assign to an attribute level. Pvalues represent the statistical difference between the preference weight of the attribute levels and
the mean effect of the same attribute [17]. If the 95% confidence interval around two levels did not
overlap, the differences between the preference weights were considered as statistically different. A
priori, we expected that the attribute levels with large improvements, heightened ability to conduct
activities, lower risk of side-effects and improvement in joint structure would have a positive effect on
utility (i.e. a positive sign).
Preferences estimate from the model was then used to calculate the conditional relative importance of
attributes overall and per country. Using the range method [17], the range of attribute-specific levels is
calculated by measuring the difference between the highest and lowest coefficient for the levels of the
respective attribute. The conditional relative importance is then calculated by dividing the attributespecific level range by the sum of all attribute level ranges. The relative attribute importance calculated
with this method always depends on the range of levels chosen per attribute and on the other
attributes included in the experiment. Given the large effect of the level “severe degradation”, we also
estimated the conditional relative importance by excluding this level.

Second, a latent class model was used to determine preference classes. Latent class models allow to
identify the existence and number of classes in the population based on their treatment
preferences [20]. To determine the number of classes, we selected the model with the best fit based
on the Akaike information criterion. The association between selected patient characteristics and
latent class membership was then determined using a multivariable logistic regression model. The
multivariable model was considered exploratory and was limited to the variables with different
probability between latent classes. This analysis was conducted with IBM SPSS 24™.

Results
Participants’ characteristics

A total of 285 questionnaires were completed and returned. Of those, 32 participants failed the
dominance test and were excluded from the final analysis. Participants who failed the dominance test
did not differ in age, gender and education level from those who passed, and inclusion of these
patients in an additional analysis did not affect the results and conclusions. The final sample consisted
of 253 participants (47 from Belgium, 31 from France, 45 from Italy, 15 from the Netherlands, 42 from
Portugal, 51 from Spain, 22 from United Kingdom). The respondents had a mean age of 71.3 years, and
74% were female. Sample characteristics are shown in Table 2. Patients had mainly lower extremely
OA (93%), with 57%, 14% and 21% of patients reporting having knee OA, hip OA and both knee and hip
OA, respectively. On average, the task difficulty was seen as moderate with an average score of 4.1,
based on responses to a seven-point scale (one for extremely easy and seven for extremely difficult).

Table 2. Patients’ characteristics.
Belgium
Failed dominance test
5
N included
47
Age, mean, years
74.3 (8.9)
Female gender
73%
Knee OA
47%
Hip OA
17%
Knee and hip OA
34%
Treatment OA
43%
Hip/knee replacement
28%
Education
Primary
4%
Some high
40%
Secondary
21%
College or University 34%
Difficulty
3.8

France
5
31
64.8 (9.7)
52%
68%
16%
7%
64%
13%

Italy
5
45
77.6 (12.5)
86%
13%
7%
7%
19%
10%

Nether.
0
15
68.1 (4.2)
67%
73%
0%
13%
33%
20%

Portugal
9
42
66.4 (11.6)
88%
36%
10%
50%
83%
15%

Spain
4
51
67.2 (11.2)
80%
96%
0%
0%
68%
12%

UK
4
22
81.8 (2.9)
55%
32%
58%
10%
67%
64%

Overall
32
253
71.3 (11.6)
74%
57%
14%
21%
54%
20%

10%
38%
24%
27%
4.1

73%
14%
7%
7%
5.2

0%
33%
20%
47%
3.6

57%
14%
14%
10%
3.4

18%
20%
31%
31%
3.8

23%
46%
4%
27%
4.5

30%
27%
18%
23%
4.1

Patients’ preference

The random parameters logit model results are presented in Table 3 and Fig. 2. In all seven selected OA
treatment outcomes, significant differences were observed between levels (as the 95% CI did not
overlap), meaning that all attributes are important for patients. All relationships were in the expected
direction, as improved levels for each attribute were associated with higher coefficients (by example,
−0.63 for no pain improvement, −0.22 for mild pain improvement, 0.25 for moderate pain
improvement and 0.61 for large pain improvement). Patients preferred thus a treatment with greater
improvement in pain, walking and/or energy, heightened ability to conduct social and domestic
activities, lower risk of side-effects, and lower structural progression. As previously mentioned, each
coefficient is estimated relative to the mean attribute effect. As example, the negative coefficient of
mild improvement in pain means therefore that this level has a lower effect on utility than the average
effect of the related attribute.

Table 3. Results from the random parameters logit model.
Attributes and levels
Pain improvement
None
Mild
Moderate
Large
Walking improvement
None
Mild
Moderate
Large
Domestic activities
All domestic activities with difficulty
Some domestic activities with difficulty
All domestic activities without difficulty
Social activities
All social activities with difficulty
Some social activities with difficulty
All social activities without difficulty
Overall energy and well-being improvement
None
Mild
Moderate
Large
Risk of severe side-effects
1 patient out of 200 within 1 year (0.5%)
1 patient out of 100 within 1 year (1%)
1 patient out of 50 within 1 year (2%)
Impact on disease progression

Estimate (95% CI) a

Standard
deviation b

−0.63 (−0.84, −0.42)⁎⁎⁎
−0.22 (−0.38, −0.07)⁎⁎
0.25 (0.10, 0.39)⁎⁎⁎
0.61 (0.42, 0.80)⁎⁎⁎

–
0.39 (0.18, 0.60)⁎⁎⁎
0.22 (−0.08, 0.53)
0.69 (0.49, 0.89)⁎⁎⁎

−0.41)⁎⁎⁎

–
0.42 (0.25, 0.60)⁎⁎⁎
0.10 (−0.21, 0.40)
0.21 (−0.06, 0.42)

−0.59 (−0.77,
−0.18 (−0.33, −0.03)⁎⁎
0.06 (−0.08, 0.19)
0.71 (0.53, 0.89)⁎⁎⁎

−0.31 (−0.48,
−0.26 (−0.37, −0.14)⁎⁎⁎
0.56 (0.41, 0.72)⁎⁎⁎

–
0.27 (0.08, 0.45)⁎⁎⁎
0.16 (−0.05, 0.37)

−0.26 (−0.45, −0.08)⁎⁎
−0.09 (−0.21, 0.03)*
0.36 (0.19, 0.52)⁎⁎⁎

–
0.29 (0.13, 0.45)⁎⁎⁎
0.29 (0.03, 0.55)⁎⁎⁎

−0.14)⁎⁎⁎

−0.31 (−0.45,
−0.05 (−0.19,0.10)
−0.09 (−0.23, 0.04)
0.45 (0.27, 0.63)⁎⁎⁎

–
0.29 (0.07, 0.50)⁎⁎⁎
0.14 (−0.15, 0.44)
0.34 (0.12, 0.55)

0.45)⁎⁎⁎

(0.23-0.54)⁎⁎⁎

−0.18)⁎⁎⁎

0.30 (0.14,
−0.03 (−0.14, 0.09)
−0.24 (−0.40, −0.09)⁎⁎⁎

0.39
0.16 (−0.02, 0.33)
–

Conditional relative importance
(without the level ‘severe
degradation’)
16.3% (20.4%)

17.1% (21.3%)

11.5% (14.3%)

8.2% (10.2%)

10.1% (12.5%)

7.4% (9.3%)

29.5% (11.9%)

Severe degradation
Mild degradation
No degradation
Improvement in joint structure

−1.61 (−1.81, −1.22)⁎⁎⁎
0.18 (0.02, 0.34)⁎⁎
0.61 (0.43, 0.80)⁎⁎⁎
0.72 (0.50, 0.94)⁎⁎⁎

–
0.93 (0.67, 1.18)⁎⁎⁎
0.84 (0.64, 1.04)⁎⁎⁎
0.60 (0.39, 0.80)⁎⁎⁎

Given the use of effects coding, the reported results for each of the attribute levels indicate the distance from average utility derived from a specific
attribute. A positive (negative) sign for a given level indicates a level has a positive (negative) effect on utility compared to the mean effect of the
attribute
b
Standard deviations correspond to the random component of the model coefficients,
⁎⁎ P<0.05,
⁎⁎⁎ P<0.01
a

Fig. 2. Patients’ preferences estimates.

Overall, given the range of levels of each attribute, the most important treatment attribute OA patient
reported was impact on disease progression (29.5%) followed by walking improvement (17.1%), pain
improvement (16.3%), ability to conduct domestic activities (11.5%), improvement in energy and wellbeing (10.2%), ability to conduct social activities (8.2%) and risk of severe side-effects (7.4%). When
excluding the level ‘severe degradation’ for the calculation of the relative importance, the conditional
relative importance of the impact on disease progression was only 12%. Given the significant standard
deviation for at least one level per attribute, variations in preferences between participants were thus
observed for all attributes, and were especially marked for impact on disease progression (see Table 3).
The conditional relative importance of attributes per country is shown in Appendix C. Given the range
of levels of each attribute, the impact on disease progression was the most important OA treatment
outcome in all countries except in Italy where pain improvement was the most important outcome. In
all countries, significant differences between levels for all seven OA treatment outcomes were
observed.

Latent class model

The latent class model identified two preferences classes with class probabilities of 56% and 44%,
respectively (see Table 4). In the first class (probability of 56%), participants valued impact of disease
progression the most (39%), and the other attributes had a score of conditional relative importance
between 5% and 14%. In the second class, walking improvement and improvement in overall energy
and well-being were the most important attributes (conditional relative importance of 23%), while
impact on disease progression was the second last attribute.

Table 4. Latent class analysis and association between patients’ characteristics and latent class membership.
Latent class 1 (56%)
Latent class 2 (44%)
P-value of the multivariable
Disease progression 39%
Disease progression 8%
logistic regression
Pain improvement 5%
Pain improvement 23%
Walking improvement 13%
Walking improvement 17%
Domestic activities 14%
Domestic activities 11%
Social activities 13%
Social activities 7%
Overall energy improv. 9%
Overall energy improv. 23%
Risk severe side-effects 11%
Risk severe side-effects 11%
Age (≥65 years)
51%
53%
Gender (female)
78%
69%
0.016
Education (≥High school) 43%
42%
Belgium
23%
12%
0.256
France
15%
8%
0.037
Italy
9%
31%
0.003
Netherlands
6%
6%
Portugal
21%
11%
0.582
Spain
17%
24%
0.844
United Kingdom
9%
9%
Knee OA
54%
63%
0.089
Hip OA
16%
10%
Knee and hip OA
26%
13%
0.826
Treatment OA
62%
43%
0.184
Hip/knee replacement
21%
20%
-

Patients from Belgium, Portugal and France were more likely to be in the class concerned mainly by the
impact on disease progression. Women, patients with hip OA and patients with OA treatment were
also more likely to be in this group. The multivariable logit model revealed three significant results:
patients from France and women were significantly more frequent in the class concerned by impact on
disease progression and patients from Italy more often in the class with a focus on walking and overall
energy. At a significance level of 10% only, patients with knee OA were also more likely to be in the
class with walking and energy improvement.

Discussion

This study demonstrates that, on average, all the seven treatment attributes we selected were
important for OA patients. Overall, given the range of levels included in our experiment, the most
important outcomes to patients were impact on disease progression and improvement in pain and
walking, although variations in preferences were observed between patients and countries. Two
preference classes were identified in the latent class analysis: one with a stronger emphasis on disease
progression, and the other on walking and pain improvement.
Overall, the conditional relative importance stated was the most important for the impact on disease
progression. This finding should however be interpreted with great caution as the relative importance
of the attributes is based on the range between the highest and lowest coefficient for the levels of the
respective attribute. A level ‘severe degradation’ was included and was associated with a strong
negative preference. Excluding this level in the calculation of the relative importance of disease
progression (i.e. estimating a difference between mild degradation and improvement in joint structure)
placed the impact on disease progression as the second least important attribute only.
Although the levels for the risk of severe side-effects were significantly different and thus important,
side-effects were less important than treatment benefits. This finding is in contrast to the study of
Hauber et al. [21] where the risk of side-effects expressed as heart-attack or stroke risk were
considered more important than benefits in ambulatory pain and doing domestic activities. The
framing of specific side-effects could potentially be more sensitive for patients than a general
description of moderate/severe side-effects. In the latent class analysis, patients from France and
women were significantly more likely to be in the class concerned mainly by the impact on disease
progression, while patients from Italy were more likely in the second latent class concerned by
improvement in walking and overall energy.
This study could have implications for research, clinical and regulatory decisions. Our study reinforces
the need to develop treatment that could influence joint structure. OA remains an unmet medical need
and some treatments have been developed but failed to develop joint structure-modifying treatments
for OA [22]. As current treatment options (including surgery, pharmacological and nonpharmacological treatment) may differ in benefits and risks, assessing patients’ preferences and
involving patients in decision-making could help to improve disease management. The findings of this
study highlight the importance of investigating individual preferences and incorporating them in a
shared-decision making process.
Although this study followed good research practices, some potential limitations exist. First, some
participants who were not cognitively able to fill out and understand the questionnaire were excluded.

Our sample could thus be slightly “over-educated” compared to the average OA patient. In addition,
our patients were mainly recruited from specialist outpatient clinics and thus may not be
representative of all OA patients visiting general practitioners. We also do not have information about
how many patients were not cognitively able to understand the questionnaire or fill them in. Thus,
selection bias and limitations in generalizability of our results cannot be excluded. Further, patients in
our study had mainly lower extremely OA (at the hip and/or knee) and preferences for OA treatment
may be different for hand or shoulder OA and would thus require further investigation. In addition, the
sample size was lower in some countries and, although significance was observed in each country, a
higher sample size would be needed to confirm findings per country. The sample size was targeted for
the whole sample and not for individual country to reveal potential differences between countries. In
our study, we therefore pooled data from all countries which could be a potential limitation. Second,
although sound methodology was used to select and define attributes including large patient
involvement, it is possible that additional attributes may play a role, at least in some countries or for
some patients. In particular, costs could be an important attribute in countries/populations where
patients have an out-of-pocket contribution. The cost attribute did not emerge as an important
attribute in our survey that mainly included patients aged over 65 years that do not have to pay for
drugs. To avoid presenting a cost attribute that would have not been relevant for most patients, we
therefore agreed to not include a cost attribute in the DCE. Similarly, mode of administration was not
considered as an important attribute in our preliminary survey and, given the constraint to limit the
number of attributes, mode of administration was not included in our list of attributes that already
contained seven characteristics. We however acknowledge that some patients may have preferences
for route of administration [23] (topical vs oral vs injection) and this would require further
investigation. To maintain consistency across countries, the same list of attributes as well as levels and
the same design was used in all countries. Third, although the working group did not consider some
combinations of levels as implausible, some could not be expected at first glance (by example being
able to have all domestic activities with difficulty and a severe impact on disease progression but all
social activities without difficulty). To avoid decreasing design efficiency, the working group agreed to
not include implausible combinations in the design. The pilot test with about 20 OA patients further did
not reveal any problems with the task. Fourth, back and forward translations of the questionnaire were
not performed, and a pilot study was not conducted in all countries. Finally, while DCEs are widely
used, an inherent limitation is that respondents are evaluating hypothetical options. Therefore, what
respondents declare they will do may differ from what they would actually do if faced with the choice
in real life.

Conclusion

This study suggests that all seven treatment attributes selected were important for OA patients.
Overall, the most important outcomes to OA patients were the impact on disease progression and
improvement in pain and walking, although variations in preferences were observed between patients.
Excluding the level “severe degradation” in the calculation of the conditional relative importance
substantially decreases the relative importance of the impact on disease progression
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